Boehringer Ingelheim India Partners with NIPER Hyderabad and Ahmedabad to Bolster National Biopharma Research

HYDERABAD:  In a landmark move for India’s pharmaceutical landscape, Boehringer Ingelheim India Private Limited has officially signed two separate Memoranda of Understanding (MoU) with the National Institutes of Pharmaceutical Education and Research (NIPER) at Ahmedabad and Hyderabad. These five-year partnerships aim to bridge the gap between academic research and industry application, focusing on two states that represent the core of India’s pharmaceutical manufacturing and biopharmaceutical exports.

The signing ceremony, held in Hyderabad, featured prominent leaders including Dr. Shailendra Saraf, Director of NIPER Ahmedabad and Hyderabad, alongside faculty from NIPER Hyderabad. This strategic alliance is designed to foster innovation through joint research initiatives, academic exchanges, and comprehensive capability-building programs.

Empowering Innovation Through Open Science:
A cornerstone of this collaboration is the provision of access to opnMe®, Boehringer Ingelheim’s global open science portal. This platform allows Indian researchers and faculty to utilize high-quality molecules—the same tools used by scientists worldwide—to explore new frontiers in early biology and drug discovery.

With more than 150 molecules already shared with Indian institutions, this expansion into Ahmedabad and Hyderabad marks a significant milestone. By placing advanced research tools in the hands of local scientists, the partnership aims to transition regional hubs from “manufacturing states” to “discovery states.”

Supporting Biopharma SHAKTI and Viksit Bharat 2047:
These agreements are deeply integrated with the Government of India’s Viksit Bharat 2047 vision and the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) mission. Announced in the Union Budget 2026-27 with a ₹10,000 crore allocation, Biopharma SHAKTI seeks to upgrade NIPER institutes into Centres of Excellence (CoE) for translational research.

Hyderabad’s role is particularly vital; as the “bulk drug capital of India” and home to Genome Valley, the city is a primary engine for the country’s biopharmaceutical ambitions. The collaboration with NIPER Hyderabad strengthens the talent pool in an ecosystem already at the forefront of vaccine and biopharmaceutical production.

A Growing National Research Network:
Following earlier 2026 agreements with NIPER institutes in Raebareli and Hajipur, Boehringer Ingelheim’s open science footprint now spans the northern, eastern, western, and southern regions of India.

Dr. Shailendra Saraf emphasized that India’s transition to an innovation-led economy depends on the strength of the academia-industry network. He noted that the speed of these signings reflects the urgency and momentum required by the Biopharma SHAKTI mission.

Meenal Gauri, Managing Director of Boehringer Ingelheim India, highlighted the long-term commitment to India’s pharmaceutical education. “In Hyderabad, where India’s biopharmaceutical cluster is most concentrated, this commitment finds a research community already focused on the national agenda,” she stated.

Operating on a non-profit and non-commercial basis, these collaborations underscore a mutual dedication to ethical research, advanced pharmaceutical education, and the broader public good.